Ranbaxy's manufacturing mess results in $606M loss

The manufacturing problems that brought about groundbreaking Department of Justice oversight of Ranbaxy Laboratories ($RBXY) has led to a $500 million charge and a $606 million loss for the fourth quarter. That loss represents the biggest quarterly loss in four years for India's largest generic drugmaker. In addition to significant lapses in its manufacturing practices, the FDA and DOJ found that Ranbaxy had falsified documentation. The consent decree forced the company to upgrade facilities, lose exclusivity on some drugs for a period and even set up an employee whistleblower program. Story | More 
 

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.